Bartter syndrome future or investigational therapies

Revision as of 21:21, 5 August 2020 by TayyabaAli (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Bartter syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Bartter syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bartter syndrome future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bartter syndrome future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bartter syndrome future or investigational therapies

CDC on Bartter syndrome future or investigational therapies

Bartter syndrome future or investigational therapies in the news

Blogs on Bartter syndrome future or investigational therapies

Directions to Hospitals Treating Bartter syndrome

Risk calculators and risk factors for Bartter syndrome future or investigational therapies

Main article: Bartter syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]

Overview

Experimental treatments that are being examined depend on the revelation that a few mutations causing Bartter syndrome create carriers with normal function. In any case, the mutations bring about the sequestration of these carriers inside intracellular compartments with the goal that they neglect to effectively embed into the suitable cell membrane. When these proteins can be effectively embedded into the cell membrane, they can become functional and correct the defect. The delivery and insertion of these fully or partially functional proteins into the cell membrane and partially rescue sodium chloride reabsorption can be improved by the utilization of the molecular chaperones, such as 4-phenylbutyrate.

Future or Investigational therapies

  • Experimental treatments that are being examined depend on the revelation that a few mutations causing Bartter syndrome create carriers with normal function. In any case, the mutations bring about the sequestration of these carriers inside intracellular compartments with the goal that they neglect to effectively embed into the suitable cell membrane. When these proteins can be effectively embedded into the cell membrane, they can become functional and correct the defect.
  • The delivery and insertion of these fully or partially functional proteins into the cell membrane and partially rescue sodium chloride reabsorption can be improved by the utilization of the molecular chaperones, such as 4-phenylbutyrate.[1][2][3]

References

  1. Andrini O, Keck M, Briones R, Lourdel S, Vargas-Poussou R, Teulon J (2015). "ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3". Am J Physiol Renal Physiol. 308 (12): F1324–34. doi:10.1152/ajprenal.00004.2015. PMID 25810436.
  2. de Jong JC, Willems PH, Goossens M, Vandewalle A, van den Heuvel LP, Knoers NV; et al. (2004). "Effects of chemical chaperones on partially retarded NaCl cotransporter mutants associated with Gitelman's syndrome in a mouse cortical collecting duct cell line". Nephrol Dial Transplant. 19 (5): 1069–76. doi:10.1093/ndt/gfg474. PMID 15102966.
  3. Peters M, Ermert S, Jeck N, Derst C, Pechmann U, Weber S; et al. (2003). "Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome". Kidney Int. 64 (3): 923–32. doi:10.1046/j.1523-1755.2003.00153.x. PMID 12911542.


Template:WikiDoc Sources